Greg Schiffman will join StemCells as chief financial officer and executive vice president of finance in January.

Schiffman previously held financial executive posts at Affymetix and Applied Biosystems. He most recently was executive vice president and CFO of Dendreon.

StemCells is Newark, Calif.-based company that specializes in cell-based therapeutics and stem cell-based R&D firm. Schiffman will succeed StemCells' current CFO, Rodney Young, when he assumes his new post next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.